Supplementary materials: Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry
收藏Mendeley Data2024-04-22 更新2024-06-26 收录
下载链接：
https://data.mendeley.com/datasets/8bbwkw2xnd
下载链接
链接失效反馈官方服务：
资源简介：
Supplementary materials related to the manuscript entitled “Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry”
与题为《度普利尤单抗（Dupilumab）对中重度特应性皮炎患者的患者报告结局（patient-reported outcomes）具有持续疗效且安全性良好：来自日常临床实践BioDay登记库的长达5年随访结果》的研究论文相关的补充材料
创建时间：
2024-04-18
